Eli Lilly and Company

Matthew Allen Schiffler

Jeremy Schulenburg York

Alan M Warshawsky

Steven Lee Kuklish

Peter Rudolph Manninen

Matthew Joseph Fisher

Prabhakar Kondaji Jadhav

Maria-Jesus Blanco-Pillado

Konstantinos Gavardinas

Tatiana Natali Vetman

Katherine Marie Partridge

Gary G Deng

Maria Jesus Blanco-Pillado

Euibong Jemes Kim

The present invention provides a compound of the Formula I: wherein A is: and W, Y, X, R, R, R, and Rare as defined herein, or a pharmaceutically acceptable salt thereof, for use as an inhibitor of the EP4 receptor. 

Dimethylbenzoic acid compounds

The present invention provides compounds of Formula (1), or a pharmaceutically acceptable salt thereof, formula (1), where R, R1, and G are as described herein; methods of preparing the compounds; and use of the compounds to treat pain and/or inflammation associated with arthritis or osteoarthritis. 

[object Object]

The present invention provides a compound of the Formula (I): wherein X, R, R, R, R, R, R, R, R, R, and Rare as defined herein, or a pharmaceutically acceptable salt thereof. 

Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators

The present invention provides a compound of the Formula II:  

Phenoxyethyl piperidine compounds

The present invention provides compounds of the formula below or pharmaceutical salts thereof, wherein R1, R2 and R3 are as described herein; methods of treating osteoarthritis using the compounds; and a process for preparing the compounds.

Imidazole-2-benzamide compounds useful for the treatment of osteoarthritis

The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof. Also, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable diluent or carrier. The present invention further provides methods for treating abdominal aortic aneurysm, plaque instability, atherosclerosis, or autoimmune disorders such as rheumatoid arthritis, psoriasis, and lupus comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

Growing community of inventors

Indianapolis, IN, United States of America

Matthew Allen Schiffler